SECTION I · THE BRIEF
Brief #91428Updated 27 AUG 2026WATERTOWN, MAGreenhouseMEDICAL ORGANIZATIONS
Employbl Company Profile

Senior Manager or Associate Director, Preclinical Safety Study Monitor

Kymera Therapeutics, Inc. operates as a biopharmaceutical company. The Company focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the…

Location
Watertown, MA
Company size
253–253
Posted
6d ago
Via
Greenhouse
Section II · Full ProfileFree with an account
  • 01Comp band & equity packageLocked
  • 02Seniority & experience requirementsLocked
  • 03Interview process & rubricLocked
  • 04Hiring manager & team contextLocked
  • 05Growth trajectory in this roleLocked
  • 06Offer & decision timelineLocked

Free account · no card · 2 minutes

Kymera Therapeutics logo

Senior Manager or Associate Director, Preclinical Safety Study Monitor · Kymera Therapeutics

View company profile
Job title
Senior Manager or Associate Director, Preclinical Safety Study Monitor
Job location
Watertown, MA
Job description

Who we are:

Kymera is a clinical-stage biotechnology company pioneering the field of targeted protein degradation (TPD) to develop medicines that address critical health problems and have the potential to dramatically improve patients’ lives. Kymera is deploying TPD to address disease targets and pathways inaccessible with conventional therapeutics. Having advanced the first degrader into the clinic for immunological diseases, Kymera is focused on building an industry-leading pipeline of oral small molecule degraders to provide a new generation of convenient, highly effective therapies for patients with these conditions. Founded in 2016, Kymera has been recognized as one of Boston’s top workplaces for the past several years. For more information about our science, pipeline and people, please visit www.kymeratx.com or follow us on X (formerly Twitter) or LinkedIn

 

How we work:

  • PIONEER: We are courageous, resilient and rigorous in our mission to improve patients’ lives through our revolutionary degrader medicines.
  • COLLABORATE: We value trust + transparency from everyone. Our goals are shared, our decisions data-driven and our camaraderie genuine.
  • BELONG: We recognize our differences, inviting curiosity and inclusivity, so that our people are valued, seen, and heard.

 

How you’ll make an impact:

Kymera Therapeutics is seeking an experienced nonclinical toxicology professional to join the Preclinical Safety organization as a Senior Manager or Associate Director, Preclinical Safety Study Monitor. This individual will serve as the study level scientific and operational lead for outsourced nonclinical safety studies, partnering with project toxicologists and CRO Study Directors to ensure high-quality, timely, and inspection-ready study execution.

  • Serve as the primary study-level scientific and operational liaison with CRO study directors and study personnel for assigned GLP and non-GLP toxicology studies (single- and repeat-dose, DRF, and specialized study designs as needed).
  • Develop, review and provide scientific input to CRO on protocols and protocol amendments, ensuring alignment with program-level nonclinical strategy and applicable regulatory expectations.
  • Monitor in-life study conduct through site visits (in person or remote), in-life reviews, and routine communication with CRO study teams; review emerging study data, monitor study quality, and identify findings or quality issues requiring discussion or escalation.
  • Attend and provide scientific input during protocol development, pre-study meetings, dose selection discussions, in-life reviews, necropsy, and pathology/TK data review.
  • Own study execution against project-critical timelines, proactively identifying risks to deliverables and implementing mitigation strategies in collaboration with the Study Manager, the Project Toxicologist, Project Manager and the CRO.
  • Review draft toxicology reports for scientific accuracy, completeness, and internal consistency prior to finalization; coordinate resolution of comments with the CRO study director.
  • Maintain accurate, audit-ready study files and documentation in Kymera's document management system (e.g., Veeva, SharePoint).
  • Coordinate activities with the Preclinical Study Manager, Project Toxicologist, DMPK, Bioanalytical, CMC and other functional areas to ensure efficient execution of nonclinical studies.
  • Independently assess study conduct issues and protocol deviations for scientific and regulatory significance and determine when escalation to Line Management or the Project Team is warranted.
  • Represent Preclinical Safety on cross-functional project teams as needed, communicating study status, risks, and scientific interpretation to non-toxicologist stakeholders.

Skills and experience you’ll bring:

  • Bachelor's or Master's degree in Toxicology, Pharmacology, Biology, Veterinary Science, or a related life science discipline.
  • Approximately 7+ years of relevant experience supporting the conduct of nonclinical safety studies, including significant experience conducting or directing toxicology studies. A minimum of 3 years of experience monitoring outsourced GLP toxicology studies at a CRO or sponsor organization is required.
  • Demonstrated experience independently managing GLP and non-GLP toxicology studies, including repeat-dose studies in rodent and nonrodent species, from protocol development through final report.
  • Strong working knowledge of Good Laboratory Practice (GLP) regulations and the conduct of nonclinical safety studies supporting global drug development, general regulatory compliance and animal welfare knowledge related to conduct of toxicology studies
  • Demonstrated ability to recognize scientific, operational, quality, and regulatory risks during study conduct and appropriately resolve or escalate issues to ensure study integrity and timely execution.
  • Excellent organizational, written, and verbal communication skills, with the ability to effectively manage multiple studies and collaborate across multidisciplinary teams and external CRO partners, in a highly dynamic, fast-paced environment.
  • Willingness to travel to CRO sites as needed (typically 5–10%).

                                                                                                                                                                                

 

Equal Employment Opportunity

Kymera Therapeutics is proud to be an equal opportunity employer, seeking to create a welcoming and diverse environment.  All applicants will receive consideration for employment without regard to race, color, religion, creed, gender, national origin, age, disability, veteran status, pregnancy, sex, marital status, gender expression or identity, genetic information, sexual orientation, citizenship, or any other legally protected class.

 

Compensation

  • Kymera offers a competitive compensation package that recognizes both results and capabilities through market-based, performance-driven pay.
  • The anticipated base salary range for this role is $145,000 – $240,000, with eligibility for annual bonus, equity participation, and comprehensive benefits.
  • Actual salary is based on a holistic evaluation of the specific role/level as well as each candidate’s depth of experience and the capabilities they bring to the position.

 

 

View job listing ↗
The Saturday Briefing

Get the Saturday tech briefing

New company profiles, funding moves, and who’s hiring across the market — every Saturday morning.

Where this role is based

Watertown, MA

Loading map…

Kymera Therapeutics headquarters

Watertown, MA

Company size

253253 employees

Founded

2017

Total raised

$1,956,800,000

View company profile ↗

Funding rounds

  • Post Ipo Equity$602M
  • Post Ipo Equity$250.8M
  • Post Ipo Equity$225M
  • Post Ipo Equity$275M
  • Post Ipo Equity$150M

    BVF Partners, Rock Springs Capital, Avoro Capital Advisors, EcoR1 Capital +2 more

  • Post Ipo Equity$257M
  • Series C$102M

    BVF Partners, Redmile Group, Bain Capital Life Sciences Fund, Wellington Management +9 more

  • IPOUndisclosed
  • Series B$65M

    6 Dimensions Capital, Bessemer Venture Partners, Pfizer Venture Investments, Aju IB Investment +6 more

  • Series A$30M

    Atlas Venture, Lilly Ventures, Amgen